Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Gilead Sciences, Inc. trades at $132.77 (market cap $163.51B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.88. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| GILD | YINN | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $56.62 |
52-Week Low | $108.22 | $21.45 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $27.85, up 7.28% with strong bullish technical signals from moving averages and oscillators. The ETF benefits from China's tech-focused stimulus and AI infrastructure investments, though key financial ratios remain unavailable for this leveraged product. Recent news highlights China's $295 billion AI buildout plan and strong export growth, creating favorable conditions for Chinese equities exposure.
The outlook remains cautiously optimistic given China's economic stimulus and tech sector momentum, but YINN's 3x leverage amplifies both gains and losses. Key risks include U.S.-China trade tensions and the inherent volatility of leveraged ETFs. Investors should consider this as a tactical trading vehicle rather than long-term holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
